🇺🇸

Broad Market

· daily

US Material Events SEC 8-K Filings — March 05, 2026

Across 84 SEC filings from March 5, 2026, dominant themes include widespread executive churn (25+ filings on appointments/departures, especially CFO/CAO roles like Sysco/McKesson swaps, Trulieve termination), robust M&A/divestiture activity (e.g., rare earth consolidation via USA Rare Earth/TMRC $73M deal, Six Flags $331M park sale), and financing enhancements (20+ credit amendments/extensions like RPM to 2031, Simon $5B rev revolver). Period-over-period trends show mixed revenue performance: growth in OptimizeRx FY2025 +19% YoY to $109.4M, Full House FY2025 +3.5% to $302.4M, Camp4 cash +71% to $109.5M, but declines in GoPro FY2025 -19% to $652M and hardware -21.5%; margins compressed in GoPro -290bps Q4 to 31.8%, flat EBITDA in Full House. Capital allocation leans shareholder-friendly with EPAM $300M ASR (remaining $452.5M program), OptimizeRx $10M buyback, AZZ board refresh for M&A/ESG. Critical implications: Positive for rare earths/tech consolidation amid supply chain risks, caution on media distress (Cumulus Ch11) and cannabis/consumer volatility; portfolio-level alpha in financing-secured growth names vs. restructuring risks.

84 high priority 84 total filings
· daily

US SEC Filings Daily Market Digest — March 05, 2026

Across 481 SEC filings for March 5, 2026, US markets show mixed corporate health with retail leaders like Burlington Stores (+9% FY sales, +2% comps) and BJ's (+4.6% FY sales) outperforming amid modest guidance (Burlington FY26 +8-10%), while consumer names like GoPro (-19% revenue) and Grove Collaborative (-15%) struggle with margin erosion. Biotech and pharma exhibit robust revenue surges (REGENXBIO +105% YoY, Lexicon +60%, Cryoport +12.4%) but persistent net losses and cash burn, offset by positive pipeline catalysts (e.g., Tenaya-Alnylam collab up to $1.13B milestones). Energy firms report production gains (Granite Ridge +27% YoY Q4, SandRidge +12% FY) and reserve growth (+9.5-15%), though revenues vary with prices; SPAC activity surges with Pasqal's $2B merger and multiple quantum deals. Portfolio trends reveal margin compression in 8/15 tech filings (avg -120bps despite +15-30% revenue), retail comp sales +1-5% avg in outperformers vs declines elsewhere, and capital returns via buybacks/dividends in 12 firms (e.g., EPAM $300M ASR, Kroger $7.5B repurchase). Insider patterns absent but management conviction via repurchases in Ranger (994k shares), Burlington ($117M Q4). Forward catalysts cluster in Q2 2026 (Northern Data acquisition, Pasqal Nasdaq listing, multiple earnings). Overall, actionable alpha in energy production plays and retail leaders amid quiet M&A uptick.

253 high priority 228 medium 481 total filings
· daily

Global High-Priority Regulatory Events — March 05, 2026

Across 285 filings from March 5, 2026, key themes include a surge in SPAC IPOs and mergers (e.g., Pasqal at $2B valuation, QuasarEdge, KPET), quantum computing catalysts (Pasqal, Xanadu), and distress in infrastructure/energy (multiple Jaiprakash defaults at ₹55k Cr debt, Cumulus Chapter 11, SKIL insolvency). Period-over-period trends show mixed revenue growth (avg +12% YoY in airlines/tech like LATAM +11%, CrowdStrike +22%; declines in media/energy like StubHub -1.4%, Stabilis -6.9%), margin compression in 15/50 quantified cos (avg -100bps, e.g., Full House EBITDA flat), and capex/debt rises amid M&A. Biotech/pharma mixed (Tenaya-Alnylam collab $1.13B milestones positive; Immatics loss swing), with positive leadership changes (SentinelOne CFO, Delta exec shuffles). Insider conviction low (no buys noted, sales rare), capital returns via buybacks (EPAM $300M ASR, Sysco reaffirmed). Portfolio-level: 40% mixed sentiment, quantum/SPAC bullish outliers, Indian insolvencies drag EM. Actionable: Monitor Q2-Q3 deal closes, CoC meetings.

285 high priority 285 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 05, 2026

Across 128 overnight SEC filings, retail and consumer sectors showed resilient top-line growth (e.g., Burlington +11% YoY sales, BJ's +5.5% Q4) but frequent margin compression (avg -100bps in 6/10 retailers) amid tariffs and costs, while biotech/pharma exhibited mixed results with strong product ramps (Liquidia +1031% revenue) offset by R&D spikes and losses. Quantum computing SPACs like Bleichroeder/Pasqal ($2B valuation, $600M proceeds) and Xanadu signal hot M&A in emerging tech, contrasting energy services' pricing pressures (Ranger Wireline -45% YoY). Capital allocation leaned shareholder-friendly with $10B+ in buybacks/dividends (Kroger $7.5B+$2B, EPAM $300M ASR, Ranger FCF >40% to repurchases/dividends). Guidance trends modest for 2026 (e.g., Burlington comps 1-3%, Kroger identical sales 1-2%) but positive outliers like Ciena raised FY26 to $5.9-6.3B (+28%). Portfolio-level: 45/128 positive sentiment, 60 mixed, 10 negative; YoY revenue growth avg +15% in winners but -20% in laggards like Silence (-99%). Key implication: Favor growth retail/biotech turnarounds with strong FCF, monitor quantum M&A redemptions.

65 high priority 63 medium 128 total filings
· daily

US Material Events SEC 8-K Filings — March 04, 2026

Across 77 US SEC filings from March 4, 2026, dominant themes include robust M&A/divestiture activity (12 deals totaling >$5B, e.g., SSR Mining $1.5B sale, Columbus McKinnon $2.7B acquisition), a surge in debt refinancings and equity offerings (25+ financings, e.g., $400M Alliant credit, $550M H2O offering) signaling liquidity needs amid mixed earnings, and high leadership churn (25+ changes, mostly neutral/positive appointments). Period-over-period trends show polarized performance: high-growth outliers like BillionToOne (+113% Q4 YoY revenue, +100% FY) and National Presto (+29.7% FY sales) contrast with decliners like Smith Micro (-20% Q4 YoY revenue) and Aquestive Therapeutics (FY revenue -3%), with average reported revenue growth ~+30% where disclosed but EBITDA/margins mixed (e.g., Babcock & Wilcox +53% Q4 EBITDA). Capital allocation leans toward debt reduction (e.g., Sabre redeemed $91.6M notes) and buybacks (Hess Midstream $60M repurchase), while one bankruptcy (Charles & Colvard) flags distress. Forward-looking catalysts cluster in Q2-Q3 2026 (M&A closes, earnings), with biotech/mining pivots to AI/critical minerals offering upside. Portfolio implications: overweight growth biotech/energy names, monitor small-cap financings for dilution risks, favor M&A active firms for synergies.

77 high priority 77 total filings
· daily

US SEC Filings Daily Market Digest — March 04, 2026

Across 433 SEC filings for March 4, 2026, mixed sentiment prevails with 60% of 10-Ks showing revenue growth (avg +12% YoY) but frequent margin compression (-120 bps avg in consumer/retail) and widened losses in 45% of cases, driven by SG&A surges (+25% avg YoY) and impairments. Consumer-facing firms like Kontoor Brands (+21% revenue YoY via acquisitions) and National Vision (+9% revenue, +56% adj op income) outperform, while energy producers like Gran Tierra (+32% production YoY but -23% EBITDA) and Xponential Fitness (flat SSS, -2% revenue) lag amid cost pressures. Capital allocation leans shareholder-friendly with buybacks/dividends in 25% of filings (e.g., Kontoor $25M remaining auth, News Corp $1B program), but dilution risks rise (US Energy 19% new shares). M&A/divestitures active (SSR Mining $1.5B sale, Ziff Davis asset sale), SPAC/de-SPAC momentum builds (Pelican, Haymaker), and financing abundant (Applied Digital $2.15B notes). Forward guidance cautious but positive in healthcare/tech (National Vision $107-133M adj op inc FY26). Portfolio trend: Rotate to margin-resilient growth (e.g., Cricut +26% op income) away from cyclical retail/energy.

215 high priority 218 medium 433 total filings
· daily

Global High-Priority Regulatory Events — March 04, 2026

Across 237 filings in the Global High Priority Market Events stream (US SEC focus, March 4, 2026), dominant themes include debt refinancings (e.g., Cooper-Standard $1.1B lower-cost notes), M&A/divestitures (SSR Mining $1.5B sale, Ziff Davis to Accenture), and distress signals like bankruptcies (Charles & Colvard Chapter 11) and insolvencies (TV Vision ₹294Cr petition). Period-over-period trends show mixed revenue growth (avg +8% YoY in reporting 10-Ks like National Vision +9%, Kontoor +21%, but declines in Xponential -2%, Sensus -34%) with widespread margin compression (e.g., 6/12 consumer firms -100-200bps avg due to SG&A rises) offset by cost savings in refinancings. Insider activity sparse but positive (Bondada promoter +0.003% stake), capital allocation leans to buybacks/dividends (Kontoor $25M remaining, Horizon $0.18 Q2 2026), while forward guidance highlights AI catalysts (Alnylam 2029 vesting at $500-800 stock price). Portfolio-level patterns flag energy/mining outperformance (Gran Tierra prod +38% YoY) vs retail weakness (Cracker Barrel rev -7.9% QoQ), with regulatory fines (BF Utilities ₹5.43L) and delistings (Vicarious NYSE suspension) amplifying volatility. Implications: Opportunistic buys in refinanced industrials, avoid distress names; monitor Q1 earnings for margin recovery.

237 high priority 237 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 04, 2026

Overnight SEC filings reveal a mixed but resilient US equity landscape, with precious metals ETFs (abrdn Gold, Silver, Platinum, Palladium, Precious Metals Basket) posting explosive YoY asset growth averaging 150-280% driven by metal price surges, contrasting margin compression and revenue declines in industrials (Eastern Co -190bps gross margin, HYSTER-YALE -12.5% revenue to net loss) and consumer (B&G Foods divestitures, Versant Media -5.3% revenue). BDCs and credit funds show portfolio expansion (e.g., 92-313 companies +43-109% commitments) but uniform yield declines to 8.5-9.2% from 9.5-10.2% amid rising leverage (5.7-6.3x), signaling caution in private credit. Tech outliers shine (Credo Technology +202% Q3 revenue to $407M, 68.5% margins), while biotech/pharma mixed with revenue volatility (Evolus +11.6%, Arcturus -46%). Governance filings dominate (50+ Nuveen DEF 14A for April 16 meetings, record dates Feb 9), neutral but highlighting virtual AGMs; SPACs (Pono, Cortigent) eye IPOs with dilution risks. Capital returns steady (buybacks/dividends in Copart, Superior Group), but restatements (ABVC revenue erased) and bankruptcies (Charles & Colvard Ch11) flag micro-cap distress. Portfolio trend: 40% positive sentiment in metals/resources, 30% mixed industrials/BDCs, implying rotation to commodities pre-market.

162 high priority 101 medium 263 total filings
· daily

US Material Events SEC 8-K Filings — March 03, 2026

Across 73 SEC filings dated March 3, 2026, dominant themes include a surge in M&A activity (10+ deals like Flowco's $200M Valiant acquisition, Esperion's $75M+ Enbumyst buy, Knightscope's Event Risk integration), extensive leadership transitions (25+ cases, mostly orderly retirements/appointments boosting expertise in healthcare/tech/energy), and robust capital markets engagement with $5B+ in debt issuances/refinancings (e.g., Leidos $1.4B notes, Vertiv $2.1B notes achieving IG status), share repurchases ($2B Pinterest ASR, $100M Trex), and equity facilities. Period-over-period trends show strong revenue growth in available data (Evolus FY2025 +12% YoY to $297M, Black Rock FY2025 +24.5% YoY to $200M, Byrna 84% CAGR to $118M), though mixed operating margins (Evolus non-GAAP loss widened, Black Rock op income -85% YoY). Positive sentiment prevails (45/73 filings), signaling sector resilience in healthcare (15 filings), energy (8), and consumer (6), with forward catalysts like Q2 2026 deal closes and H1 earnings. Portfolio-level patterns highlight undervalued buybacks amid M&A premiums (e.g., Select Medical 25% premium), but liquidity strains in biotechs (Karyopharm going concern). Implications: Bullish for M&A arbitrage and growth stocks, cautious on small-cap distress.

73 high priority 73 total filings
· daily

US SEC Filings Daily Market Digest — March 03, 2026

Across 385 SEC filings for March 3, 2026, healthcare and biotech dominate with 45+ earnings/milestones showing mixed YoY revenue growth averaging +25% (e.g., Rigel +41%, Strata Critical +83.5%) but persistent net losses narrowing in 60% of cases; retail reports mixed comp sales (-2.5% Target to +9% Ross Stores) with margin expansion in resilient names (Best Buy +360bps to 5.2%). M&A activity surges with 15+ deals (e.g., Select Medical $16.50/share premium, RAPT $58/share acquisition), while financings/debt issuances exceed 50 (e.g., TXNM $125M ATM, Reinsurance Group $400M notes). Capital returns strong: 20+ dividends/buybacks (Best Buy div +1%, Pinterest $2B repurchases). Portfolio trends: margins compress in 7/15 industrials (-150bps avg) but expand in consumer/health (+200bps avg); insider conviction low volume but positive (e.g., no major sells). Neutral ETF/prospectus filings (120+) signal routine compliance. Forward catalysts cluster mid-2026 (Phase 3 data, mergers). Overall, bullish on healthcare catalysts, cautious retail/debt-heavy names amid going concern flags (3 cases).

207 high priority 178 medium 385 total filings
· daily

Global High-Priority Regulatory Events — March 03, 2026

Across 236 filings dominated by US SEC 8-Ks and routine fund prospectus certifications (497J/K ~60%), critical themes include robust M&A/takeover activity (e.g., Select Medical $3.9B EV at 25% premium, Flowco $200M acquisition, Knightscope bolt-on), leadership transitions (positive in Byrna, Wyndham; neutral elsewhere), and capital raises/refinancings (TXNM $125M ATM, Leidos $1.4B notes for ENTRUST). Period trends show mixed revenue growth: Evolus Q4 +14% YoY/$90.3M, Black Rock Coffee Q4 +25.3% YoY/$53.6M but FY net loss -130% to $16.5M; margins compressed in some (RYAM Q4 EBITDA -$5M YoY). Indian firms faced clustered SEBI fines for board non-compliance (e.g., Bharat Heavy, Hindustan Copper ~₹5-10L each, 10+ cases), signaling governance risks. Forward guidance stable/positive (Evolus 10-13% rev growth 2026, Wyndham reaffirmed), with capital returns via dividends (Mangalore ₹4/share, 40%, record Mar 11), buybacks (Pinterest $2B H1 2026), and debt optimization (Reinsurance $396M net, Vertiv IG upgrade). Portfolio-level: Healthcare M&A bullish, energy financings neutral, funds neutral (low materiality). Implications: Tactical opportunities in take-private premiums, monitor Indian governance for shorts, favor US growth names amid stable guidance.

236 high priority 236 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 03, 2026

Overnight SEC filings (626 total) dominated by routine 497K/J fund prospectuses (95%+ volume) showing pervasive mixed/neutral sentiment with most active funds underperforming S&P 500 benchmarks long-term (e.g., 10/12 Hennessy funds trailed 14.82% 10Y return avg by 200-500bps) amid high turnover (avg 80%) and sector concentrations, signaling caution on active mid/small-cap strategies vs passive indices. Operational companies highlighted positive milestones like Aptera's first vehicle production (+8/10 materiality) and Byrna's revenue 84% CAGR under retiring CEO, but mixed earnings (Limbach rev +25% YoY yet GCR -7%, AutoZone SSS +3.3% but margins -137bps). Biotech M&A active (Rallybio/Candid $750M rev merger diluting legacy holders to 3.65%; Freenome de-SPAC H1 2026) with positive pipeline catalysts; SPAC/control changes (Slam Corp full equity shift to crypto/DeFi experts). Capital allocation bullish in repurchases (NRG $300M, BrightSpring $60M potential) but insider selling patterns in funds/mixed signals. Portfolio trend: margin compression avg -100bps in 6/10 detailed earnings despite rev growth +15% avg YoY; forward catalysts cluster Q2 2026 (FDA nods, mergers). Implications: favor passive ETFs/index hugging, monitor biotech/SPAC dilutions, buy dips in infra/energy acquirers.

568 high priority 58 medium 626 total filings
· daily

US Material Events SEC 8-K Filings — March 02, 2026

Across 112 SEC filings from March 2, 2026, a dominant theme is aggressive M&A activity, particularly in banking (10+ mergers like HBT Financial, Farmers National, First Mid Bancshares) expanding assets 20-42% and footprints, signaling sector consolidation amid stable rates. Biotech/pharma sees 15+ deals/financings (e.g., Zymeworks $250M royalty note, Gyre-Cullgen $300M merger, Kairos CL-273 license) bolstering pipelines with FY2027 revenue projections up to $200M+. Strong period trends include revenue growth in tech (MongoDB +27% YoY Q4 FY2026 to $695M, Dave Inc +62% YoY Q4 2025 to $164M) and production upticks (Kosmos +4% QoQ to 67.9k boepd), though mixed with impairments/losses; capital allocation favors accretive buybacks/dividends (Zymeworks stock repurchases, Great Elm $0.30/share Q1 dividend). Leadership churn is high (30+ appointments/retirements) but mostly orderly/positive, enhancing expertise in finance/risk. Energy firms like Kosmos/Tilray pursue accretive asset deals ($220M EG sale, BrewDog acquisition for $200M rev), while SPACs/offerings (Illumination $200M IPO, Fortress $250M) indicate bull market for listings. Overall bullish M&A momentum (25+ deals) outweighs risks like restructurings (BioAtla 70% layoffs), positioning investors for catalysts in Q2-Q3 2026 closings.

112 high priority 112 total filings
· daily

US SEC Filings Daily Market Digest — March 02, 2026

Across 327 SEC filings for March 2, 2026, mixed sentiment dominates (appearing in 15+ filings like Norwegian Cruise, Venture Global, Ruger), with revenue growth strong in energy (Venture Global +177% YoY to $13.8B, Kosmos Q4 +4% QoQ) and biotech but profitability pressures evident (Ruger FY net loss vs prior profit, WhiteHorse NII -29.8% YoY). Biotech shines with positive Phase 3 data (DBV 46.6% responders, United Therapeutics 55% risk reduction) and catalysts into H1 2026 (BLA submissions, PDUFA Mar 20). M&A activity surges (Warner Bros $81B deal, Malibu Boats accretive acquisition at 7.2x EBITDA, HBT $1.8B assets), alongside capital returns (ADMA $200M buybacks, Klaviyo $500M program). Period trends show YoY revenue acceleration in 20+ cos (avg +20-50% in LNG/pharma) but margin compression in 10+ (avg -100-200bps consumer/manufacturing). Insider sales at Coca-Cola Europacific (execs sold $1.4M) contrast buybacks signaling conviction elsewhere. Forward guidance mixed: flat yields (Norwegian), $5.2-5.8B EBITDA (Venture), but Whirlpool EPS cut ~$1. Implications favor selective longs in biotech/energy catalysts, caution consumer/retail amid traffic declines.

132 high priority 195 medium 327 total filings
· daily

Global High-Priority Regulatory Events — March 02, 2026

Across 158 filings on March 2, 2026, dominant themes include a surge in US banking M&A (e.g., HBT Financial +42% assets, Farmers National +42% assets to $7.4B), positive capital allocation via buybacks (Go Fashion ₹65Cr) and accretive acquisitions (ITT SPX FLOW $4.8B, Malibu Boats $175M at 7.2x EBITDA), contrasted by distress in Indian firms with defaults (Siti Networks ₹1,206Cr claims, Ansal Housing ₹50Cr principal) and tax raids (Greenpanel). Period trends show revenue strength in select names (Dave Inc. Q4 +62% YoY to $164M, MongoDB Q4 +27% YoY to $695M, Kosmos Q4 prod +4% QoQ) but mixed margins (MongoDB flat GAAP gross at 73%). Leadership transitions are prevalent (neutral sentiment, e.g., Eaton CFO change, Civista CEO succession), with forward catalysts like open offers (Shantai Apr 2026) and deal closes (EQV Mar 4). Portfolio-level: Banking consolidation boosts scale (avg +35-42% assets in deals), Indian realty/media under pressure (5/10 high materiality negatives), energy/biotech M&A outliers for growth. Implications: Favor US consolidators for synergies, avoid Indian defaulters amid CIRP; watch SPAC de-SPACs and debt refinancings for liquidity plays.

158 high priority 158 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 02, 2026

Across 121 overnight SEC filings, dominant themes include a surge in M&A activity (10+ deals like Warner Bros. Discovery's $81B merger with Paramount Skydance, HBT Financial's completion with CNB adding $1.8B assets, Malibu Boats' $175M Saxdor acquisition), robust biopharma catalysts (United Therapeutics' 55% risk reduction in Phase 3, Rhythm's PDUFA March 20 for setmelanotide, DBV's Phase 3 responder rate 46.6%), and mixed financial results with 15+ companies showing YoY revenue growth averaging 30-50% (e.g., Venture Global +177%, RadNet +14.8%) but margin pressures in consumer/energy (avg -100bps compression in 8/20 cases). Capital allocation leans bullish with 12+ share repurchase programs (Klaviyo $500M, ADMA $200M, Zymeworks $62.5M used), dividend hikes (PROG +7.7%), and debt reductions (Bandwidth repurchased $100M notes). Energy/oil firms highlight strong production/revenue but impairments (Kosmos Q4 loss $377M), while REITs show leasing gains (Macerich 7.1M sq ft). Portfolio-level: 60% positive/mixed sentiment, implying pre-market upside in biopharma/media, caution in cruise/retail; no major insider selling patterns, but buys/exercises signal conviction (WhiteHorse 1.1M shares $8M, Ramaco CEO options). Forward catalysts cluster in H1-H2 2026 (NDAs, earnings, closings).

41 high priority 80 medium 121 total filings
· daily

Global High-Priority Regulatory Events — February 28, 2026

Across 7 high-priority filings centered on insolvency resolutions, encumbrances, and corporate actions, a dominant theme is positive progress in insolvency proceedings for 4 companies (Ramkrishna Forgings, Embassy Developments, Sayaji Hotels, Punj Lloyd), signaling operational continuity and asset sales amid India's restructuring wave, offsetting negative promoter encumbrances in IndiaFinsec and TANFAC. No explicit period-over-period financial trends like YoY revenue growth or margin compression are detailed, but merger synergies and stayed insolvencies imply stabilized operations versus prior distress. High materiality events (avg 7.7/10) highlight critical market events in manufacturing, real estate, hospitality, IT, chemicals, and defense sectors. Promoter pledges/encumbrances on significant holdings (e.g., 25.8% in TANFAC) raise liquidity concerns and potential share disposal risks. Routine TCS auditor rotation adds neutral stability. Overall, portfolio-level pattern shows 57% positive sentiment, favoring turnaround plays but caution on promoter leverage.

7 high priority 7 total filings
· daily

US Material Events SEC 8-K Filings — February 27, 2026

Across 97 8-K filings from February 27, 2026, dominant themes include aggressive capital raising via debt issuances ($200M-$2.5B notes across Tandem, Wyndham, Royal Caribbean, etc.), equity offerings/ATM programs (e.g., $15M Birchtech, $1.75B American Healthcare REIT), and SPAC IPOs ($125M-$261M), signaling robust liquidity pursuits amid neutral-to-positive sentiment in 70% of cases. M&A highlights feature Paramount Skydance's $81B acquisition of Warner Bros. Discovery (7.5x 2026 EBITDA) and Netflix's $2.8B termination fee from the failed WBD deal, reshaping media landscapes. Governance churn is prevalent (25+ officer/director changes, mostly retirements without disagreements), while distressed financings (e.g., 28.6% discount notes for IMAC) and delistings (reAlpha, Avidity) flag microcap risks. No broad period-over-period trends emerge due to event-driven nature, but forward-looking catalysts like Q3 2026 WBD close, annual meetings (e.g., May 2026), and note maturities (18-36 months) dominate. Portfolio implications favor large-cap refinancings reducing costs (e.g., Wyndham, WESCO) over small-cap dilution risks, with media/tech outliers driving alpha.

97 high priority 97 total filings
· daily

US SEC Filings Daily Market Digest — February 27, 2026

Across 298 SEC filings dated February 27, 2026, a dominant theme is earnings season with 50+ Item 2.02 disclosures (e.g., Amneal Pharma, Cigna, BrightSpring), mostly neutral due to undisclosed metrics, signaling steady but unremarkable Q4/FY2025 results amid quiet markets. Portfolio-level trends show mixed performance: revenues grew YoY in detailed reporters like US Antimony (record highs), Precipio (+30%), American Integrity (+23% premiums), but declined in others like Where Food Comes From (-3.3%), Gogo (ATG aircraft -9%); margins compressed in REITs/hospitality (Apple Hospitality EBITDA -190 bps) while improving in insurance (American Integrity combined ratio -17 ppts). Critical developments include 5 delistings/notices (Datavault AI, reAlpha Tech, Envoy Medical bearish; Sphere 3D regains compliance bullish), $2.8B Netflix termination fee from failed WBD deal, and $200M+ capital raises/debt refinancings (Tandem Diabetes, Ameren $891M bonds, Wyndham $650M notes). M&A activity surged with 20+ Item 1.01 (e.g., Amazon, AIR Industries neutral), insider changes neutral, but positive capital allocation via dividends/buybacks in 15+ (Healthcare Realty $50M repurchases, REIT distributions). Sector patterns favor energy/mining (US Antimony contracts), REITs (guidance intact), but flag biotech delistings and accounting restatements (Elauwit non-reliance). Implications: Favor defensive dividend payers/turnarounds; avoid small-cap delisting risks; monitor Q1 guidance for margin trends.

115 high priority 183 medium 298 total filings
· daily

Global High-Priority Regulatory Events — February 27, 2026

Across 140 filings centered on February 27, 2026, dominant themes include robust debt refinancing and issuance activity (e.g., Wyndham $650M notes, WESCO $1.5B at lower 5.25-5.50% rates vs prior 7.25%), SPAC IPOs and business combinations (e.g., Clearthink $125M, Mozayyx $261M, IQM/RAAQ quantum computing deal), and frequent executive changes/departures (neutral in 20+ cases like Tandem, Iridium, Western New England). Bearish pressures from Nasdaq delisting/deficiency notices (9 cases: Datavault, reAlpha, Envoy, Jupiter, Ensysce, Tenon, CIMG) and insolvencies (10+ medium-risk, mostly Indian firms like Heranba, Reliance). Warner Bros. Discovery's 10-K shows revenue -5% YoY to $37.3B but operating income turnaround from -$10B loss to $738M profit, with Streaming EBITDA +102% to $1.37B; no broad PoP trends but aggregate capital raises exceed $5B+. Media M&A peaks with PSKY $81B WBD takeover (7.5x 2026 EBITDA) and Netflix $2.8B termination fee. Portfolio implication: Favor liquidity-strong firms amid small-cap listing risks; watch Q3 2026 deal closes.

140 high priority 140 total filings